Delivery of Cell, RNA and DNA Therapeutics | Surveying the Business and IP Landscape

The rapidly growing pipeline of promising cell and gene therapy candidates has created a growing focus on delivery technology that safely and effectively allows these therapies to reach their disease targets in humans. Merger and acquisition activity is heating up over companies with strong delivery technology for cell and gene therapy products, such as Catalent’s $1.2 billion purchase of Paragon, a leading viral vector development and manufacturing company. The successful launch of the Pfizer-BioNTech and Moderna mRNA COVID-19 vaccines has further validated the future of therapeutics in these areas.

Foley partners Steve Maebius and Tianran Yan, Foley patent agent Jennie Zheng, and biotechnology investment analyst Shaun Mehra addressed the key business and intellectual property considerations driving activity in this area, while providing insights into the latest trends impacting successful business and patent strategies.

CLE Information

Foley & Lardner LLP will apply for CLE credit after the program, wherever applicable. Foley & Lardner LLP certifies that this activity has been approved for California MCLE credits by the State Bar of California in the amount of up to 1.0 General Credit. Foley & Lardner LLP is a State Bar of California MCLE approved provider. Please note that participants must be in attendance on the date of the event; credit may not be obtained by viewing and/or listening to a program recording after the event. Certificates of attendance will be distributed to eligible participants approximately eight weeks after the program via email. Important information for New York attorneys: This program is appropriate for experienced attorneys only.